Greenwich LifeSciences Past Earnings Performance
Past criteria checks 0/6
Greenwich LifeSciences's earnings have been declining at an average annual rate of -35.2%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
-35.2%
Earnings growth rate
-9.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -210.6% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
We Think Greenwich LifeSciences (NASDAQ:GLSI) Can Afford To Drive Business Growth
Aug 22
Greenwich LifeSciences: Trying To Move A Needle That Doesn't Like To Budge
Jun 26Here's Why We're Not Too Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Situation
Jan 12We're Not Very Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Rate
Jan 29Greenwich LifeSciences: Persevering CEO And Interesting Data
Sep 06Greenwich LifeSciences halts stock buyback program
Jul 11Greenwich LifeSciences: A First Look
May 19Greenwich LifeSciences: Insider Buying And Buybacks Telegraph This Company's Vast Potential
Apr 21Companies Like Greenwich LifeSciences (NASDAQ:GLSI) Are In A Position To Invest In Growth
Feb 01We Think Greenwich LifeSciences (NASDAQ:GLSI) Can Afford To Drive Business Growth
Sep 30We're Not Very Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Rate
Apr 04Are Insiders Buying Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock?
Feb 16
What Is The Ownership Structure Like For Greenwich LifeSciences, Inc. (NASDAQ:GLSI)?
Dec 25Greenwich LifeSciences: Optimism On 'GP2' Breast Cancer Immunotherapy Candidate
Dec 23Greenwich LifeSciences under stress on pricing upsized $26.4M equity offering
Dec 18Greenwich LifeSciences inks deal with Westport Bio for pre-clinical coronavirus vaccine candidates
Dec 15Greenwich LifeSciences trebles in value as breast cancer therapy shines in mid-stage trial
Dec 09Revenue & Expenses Breakdown
How Greenwich LifeSciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -10 | 2 | 9 |
| 30 Jun 24 | 0 | -10 | 2 | 9 |
| 31 Mar 24 | 0 | -9 | 2 | 8 |
| 31 Dec 23 | 0 | -9 | 2 | 8 |
| 30 Sep 23 | 0 | -9 | 2 | 8 |
| 30 Jun 23 | 0 | -9 | 2 | 7 |
| 31 Mar 23 | 0 | -8 | 2 | 7 |
| 31 Dec 22 | 0 | -8 | 2 | 6 |
| 30 Sep 22 | 0 | -7 | 1 | 6 |
| 30 Jun 22 | 0 | -6 | 1 | 5 |
| 31 Mar 22 | 0 | -6 | 1 | 5 |
| 31 Dec 21 | 0 | -5 | 1 | 4 |
| 30 Sep 21 | 0 | -3 | 1 | 2 |
| 30 Jun 21 | 0 | -3 | 1 | 2 |
| 31 Mar 21 | 0 | -2 | 1 | 1 |
| 31 Dec 20 | 0 | -2 | 1 | 1 |
| 30 Sep 20 | 0 | -1 | 0 | 1 |
| 30 Jun 20 | 0 | -1 | 0 | 1 |
| 31 Mar 20 | 0 | -4 | 1 | 3 |
| 31 Dec 19 | 0 | -3 | 1 | 3 |
Quality Earnings: GLSI is currently unprofitable.
Growing Profit Margin: GLSI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GLSI is unprofitable, and losses have increased over the past 5 years at a rate of 35.2% per year.
Accelerating Growth: Unable to compare GLSI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GLSI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: GLSI has a negative Return on Equity (-210.64%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 15:31 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Greenwich LifeSciences, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yi Chen | H.C. Wainwright & Co. |